Acrux and its partner Padagis announced the launch of an AB-rated generic version of Emla® Cream in the United States. Emla® (prilocaine 2.5% and lidocaine 2.5%) Cream is indicated as a topical anaesthetic for use on: normal intact skin for local analgesia; and genital mucous membranes for superficial minor surgery and as pre-treatment for infiltration anaesthesia.